Stanbio Laboratory announced that the FDA has approved its HemoPoint H2 Hemoglobin Data Management System (DMS), which provides both a hemoglobin and calculated hematocrit result with one simple test. The new, HemoPoint H2 DMS utilizes connectivity to PCs via Bluetooth, control intervals and barcode identification of operators and patients to offer time-saving convenience, ease of data management technology and high quality control.

InfraScan has  received the European marketing clearance (CE mark), for its handheld brain hematoma detector. This approval certifies that Infrascanner has met all the safety, health and environmental standards set up by European Union (EU). The diagnostic device is the first of its kind used for identification of fatal brain hematomas, thereby facilitating treatment critical to the recovery of patients. A portable device, Infrascanner is now pursuing applications for monitoring stroke victims with the use of the same technology.

The U.S. Food and Drug Administration has cleared the Tosoh G8 which offers pinpoint precision with the industry’s lowest CVs of less than 2%. The instrument-reagent system uses the gold standard ion-exchange method of HbA1c levels testing to monitor glycohemoglobin in diabetic patients effectively. The system’s automatic start-up and touch-screen operation make it very user-friendly. Also, it fits in most of the laboratory environments easily. The G8 is a diagnostic system for measurement of HbA1c in samples of blood.

Designer and manufacturer of NOVA™ (Non-invasive Optimal Vessel Analysis), VasSol, Inc. has announced that the technology will now be available in European markets. The company entered into a partnership with Tekmed Instruments, its Italian distributor, during the last month. NOVA™ is a non-invasive tool for the measurement of blood flow. The Quantitative MRA software does not need a contrast solution to be injected. Nor is there a requirement to expose the patient to radiation. The technology has useful vascular applications.

Researchers have come up with a new test that can determine whether the mother and baby are going to have different blood types or not. Published on bmj.com, the study further says that the test may substantially reduce unnecessary treatment. The baby’s blood group is predicted by typing its DNA in RhD negative pregnant women’s plasma.

Photo by enor